BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

CytoReason

CytoReason logo

Founded
2016
Publications
5

Technologies

AI Companies (Drug Discovery)

CytoReason turns human clinical data into clear biology, to deliver data-driven target discovery and drug development. CytoReason’s access to unmatched proprietary and public data, combined with cutting-edge machine learning technologies, creates our unique biological models of disease, tissue and drug. Using our molecular-level disease models we turn human clinical data into biology, mapping what the cells, genes and proteins are doing in a disease, tissue and treatment environment. This enables us to uncover disease and drug mechanisms of action and turn that biology into clinical edge, by delivering valuable IP in the form of novel targets, indications, combinations and biomarkers.

data mining drug discovery


Posts Mentioning This Company

What Makes Israel's Life Sciences Ecosystem Successful?

  
Israel's biotech sector has been considered secondary to its thriving Medtech field for decades. Still, the turn of millennia brought a significant shift to the biotech landscape in the country. Part of the growth originates from Israel’s focus on building a solid education with roughly 6% of GDP being spent on …

Pharmaceutical Giants Are Chasing R&D Deals With Smaller AI Startups

  
The first month of 2019 is not over yet, but there are already four major announcements about new research projects between large drug discovery corporations and smaller artificial intelligence (AI) companies -- this is more than the number of all similar announcements in the year 2014 combined -- only three.
SHARE